Welcome to our dedicated page for FMC SEC filings (Ticker: FMC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
FMC Corporation filings document the regulatory record of a NYSE-listed agricultural sciences company with common stock trading under FMC. Recent 8-K reports disclose operating results, material credit-agreement amendments, financial covenants, subsidiary guarantees, collateral arrangements, dividend limitations, restructuring charges, and governance changes.
Proxy materials describe annual meeting matters, stockholder voting procedures, and equity incentive plan approvals. Together, the filings cover FMC's capital structure, board oversight, compensation programs, manufacturing footprint actions, risk-related covenant terms, and recurring financial reporting for its crop protection business.
Verduin Patricia reported acquisition or exercise transactions in this Form 4 filing.
FMC Corp director Patricia Verduin reported receiving 18 shares of FMC common stock. The shares were granted at $0.00 per share, issued as dividend equivalent rights connected to her vested restricted stock units, rather than bought on the open market.
After this grant, she directly owns 7,151 shares of FMC common stock. Dividend equivalent rights provide additional shares to mirror dividends that would have been paid on underlying equity awards.
BRONDEAU PIERRE R reported acquisition or exercise transactions in this Form 4 filing.
FMC CORP Chairman, CEO and President Pierre R. Brondeau received a grant of 29 shares of Common Stock on April 16, 2026. The shares were issued at no cost through dividend equivalent rights tied to vested restricted stock units. Following this award, he directly holds 568,046 FMC shares, reflecting routine equity-based executive compensation rather than an open-market purchase or sale.
FMC Corp: The Vanguard Group filed a Schedule 13G/A (Amendment No. 15) reporting that it beneficially owns 0 shares of FMC Common Stock, representing 0% of the class. The filing notes an internal realignment of The Vanguard Group on January 12, 2026, and states certain subsidiaries now report ownership separately in reliance on SEC Release No. 34-39538. The filing is signed by Ashley Grim, Head of Global Fund Administration, dated 03/26/2026.
FMC Corporation is asking stockholders to vote at its virtual 2026 Annual Meeting on April 28, 2026 at 2:00 p.m. EDT. Holders of common stock as of February 27, 2026, when 125,045,033 shares were outstanding, may vote online, by phone, by internet or by mail.
Stockholders will elect ten directors, ratify KPMG LLP as 2026 auditor, and cast an advisory vote on executive compensation after only 50.56% supported the prior say‑on‑pay resolution. The Board highlights changes to severance, CEO pay structure, PSU design and a simplified EBITDA-based annual bonus metric.
Several governance changes are proposed: eliminating supermajority voting provisions, replacing supermajority standards for certain business combinations with majority thresholds, and giving stockholders owning at least 25% of common stock the right to call special meetings. Miscellaneous charter updates would modernize purpose, preemptive rights and other provisions.
FMC also seeks approval of the 2026 Incentive Stock Plan, allowing up to 5,250,000 new shares plus shares remaining and recycled from the 2023 plan, with a fungible share pool, no evergreen feature, minimum one‑year vesting, director pay caps and explicit anti‑repricing and clawback provisions. As of December 31, 2025, common stock outstanding was 124,934,056 shares, with 3,403,875 options and stock appreciation rights and 1,075,121 full‑value awards outstanding; 2,526,358 shares remained available under the 2023 plan.
FMC Corporation director Michael F. Barry reported an open-market purchase of 18,072.191 shares of FMC common stock on March 4, 2026. The weighted average purchase price was $13.83 per share, with individual trades executed between $13.77 and $13.86. Following this transaction, Barry directly owns 19,634.191 FMC shares.
BARRY MICHAEL F reported acquisition or exercise transactions in this Form 4 filing.
FMC Corp director Michael F. Barry received a grant of 1,562 shares of FMC common stock on February 27, 2026. The award was recorded at a price of $0.00 per share, reflecting a stock-based compensation grant rather than an open-market purchase. After this grant, his direct holdings total 1,562 shares.
FMC Corp director Michael F. Barry reported his initial ownership position as of February 27, 2026, showing no FMC common stock held directly and stating that he does not hold any FMC derivative securities. This establishes a baseline disclosure of his current equity stake at zero.
FMC Corporation is soliciting proxies for its 2026 Annual Meeting of Stockholders. The virtual meeting is scheduled for April 28, 2026 at 2:00 p.m. EDT and will be accessible at www.virtualshareholdermeeting.com/FMC2026. The record date for voting was February 27, 2026, and there were 125,045,033 shares of Common Stock outstanding on that date.
The Board asks stockholders to vote on: election of ten directors; ratification of KPMG LLP as auditor; an advisory vote on executive compensation; amendments to the Certificate of Incorporation and By-Laws (including elimination of supermajority provisions and special meeting rights at a 25% threshold); miscellaneous charter changes; and approval of the FMC Corporation 2026 Incentive Stock Plan, which proposes a reserve of 5,250,000 shares plus certain recycled shares and includes limitations such as a fungible share pool and director compensation caps.
FMC Corporation is a global agricultural sciences company focused on crop protection chemicals and plant health products, operating as a single business segment. The company is undergoing a strategic review announced in February 2026 to explore options, including a potential sale, to enhance shareholder value while it executes 2026 priorities such as strengthening the balance sheet and divesting its India commercial business, which is classified as held for sale and expected to close in 2026.
FMC is reshaping its cost base: 2024 restructuring delivered $165 million in savings and the multi‑year Project Foundation aims to optimize manufacturing and reduce structural costs. Growth is anchored by core diamide insecticides, including Rynaxypyr active with about $0.8 billion in 2025 revenue and Cyazypyr active with about $0.4 billion, alongside new herbicide and fungicide molecules and digital tools like the Arc farm intelligence platform.
The company emphasizes sustainability and safety, reporting a Total Recordable Incident Rate of 0.1491 and reducing Highly Hazardous Pesticides to roughly 0.1% of sales. As of December 31, 2025, FMC had about 5,500 employees worldwide and 124,934,056 common shares outstanding, supported by a substantial global patent estate protecting key technologies.